We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Technology Detects Blood Clots With Simple POC Test

By LabMedica International staff writers
Posted on 25 May 2016
Patients with cardiovascular disease, hypertension, atrial fibrillation, congestive heart failure, kidney disease and others who are at risk for blood clotting are especially vulnerable when blood-thinning medication levels get too weak or too strong.

A test has been designed to give each patient the ability to keep a careful check on their levels by monitoring the changes that occur relative to previous tests. More...
The technology can also be calibrated to a specific patient's condition. For example, a patient whose normal blood coagulation rate is significantly different from the general population because of a genetic disorder can use a tailor-made test kit that includes a different porous membrane.

Scientists at the University of Cincinnati (OH, USA) used nanofiber membranes inside paper-based porous materials housed within a plastic cassette, which can quickly reveal the level of the blood's ability to clot, and all from the convenience of the patient's home with a simple finger stick to draw a drop of blood. While slight changes in the level of coagulation properties will occur normally depending on certain food intake and overall health conditions. A major change in levels immediately shows up on the paper-based test stick resulting in clotting patterns registering on one end of the spectrum or the other and will put up a red flag before any physiological trouble starts.

Andrew Steckl, PhD, a professor of electrical engineering, said, “We have developed a blood screening device for patients on medications like Coumadin, warfarin or other blood thinners who need to monitor their blood-clotting levels on a regular basis. Patients can soon monitor their blood coagulation characteristics from home quickly and painlessly before making needless trips to the laboratory or hospital. By identifying potential blood-clotting problems early enough, we hope to prevent potential injury or death and the exorbitant associated costs.” The study was presented at the 8th International Conference on Porous Media and Annual Meeting of the International Society for Porous Media, held May 9-12, in Cincinnati, OH, USA.

Related Links:
University of Cincinnati


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Online QC Software
Acusera 24•7
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.